DNA repair targeted therapy: The past or future of cancer treatment?

Pharmacology and Therapeutics

Volumn 160, Issue , 2016, Pages 65-83

  Gavande, Navnath S ^a   Vandervere Carozza, Pamela S ^a   Hinshaw, Hilary D ^a   Jalal, Shadia I ^a   Sears, Catherine R ^a   Pawelczak, Katherine S ^b   Turchi, John J ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NERx Biosciences   (United States)

Author keywords

Cancer; DNA damage; DNA repair; Radiation; Replication protein A

Indexed keywords

ANTINEOPLASTIC AGENT; DNA LIGASE; DOUBLE STRANDED DNA; GENOMIC DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RAD51 PROTEIN; DNA; DNA ADDUCT;

CANCER CELL; CANCER RADIOTHERAPY; CANCER THERAPY; DNA ADDUCT; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DRUG SCREENING; ENERGY METABOLISM; EXCISION REPAIR; FANCONI ANEMIA; GENE MUTATION; GENETIC CODE; GENETIC STABILITY; HUMAN; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; MISMATCH REPAIR; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOSENSITIZATION; REVIEW; ANIMAL; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA; DNA ADDUCTS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; NEOPLASMS;

EID: 84959561469     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.02.003     Document Type: Review

References (174)

1. R. Abbotts, R. Jewell, J. Nsengimana, D.J. Maloney, A. Simeonov, C. Seedhouse, and et al. Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy Oncotarget 5 2014 3273 3286
2. D.A. Alagpulinsa, S. Ayyadevara, and R.J. Shmookler Reis A small-molecule inhibitor of RAD51 reduces homologous recombination and sensitizes multiple myeloma cells to doxorubicin Front Oncol 4 2014 289
3. R.I. Al-Safi, S. Odde, Y. Shabaik, and N. Neamati Small-molecule inhibitors of APE1 DNA repair function: an overview Curr Mol Pharmacol 5 2012 14 35
4. V.E. Anderson, M.I. Walton, P.D. Eve, K.J. Boxall, L. Antoni, J.J. Caldwell, and et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors Cancer Res 71 2011 463 472
5. S.A. Andrabi, G.K. Umanah, C. Chang, D.A. Stevens, S.S. Karuppagounder, J.P. Gagne, and et al. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis Proc Natl Acad Sci U S A 111 2014 10209 10214
6. B.J. Andrews, and J.J. Turchi Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair Mol Cancer Ther 3 2004 385 391
7. M. Andrs, J. Korabecny, D. Jun, Z. Hodny, J. Bartek, and K. Kuca Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring J Med Chem 58 2015 41 71
8. A.A. Antolin, and J. Mestres Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors Oncotarget 5 2014 3023 3028
9. D. Arian, M. Hedayati, H. Zhou, Z. Bilis, K. Chen, T.L. DeWeese, and et al. Irreversible inhibition of DNA polymerase beta by small-molecule mimics of a DNA lesion J Am Chem Soc 136 2014 3176 3183
10. S. Arora, A. Kothandapani, K. Tillison, V. Kalman-Maltese, and S.M. Patrick Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells DNA Repair (Amst) 9 2010 745 753
11. AstraZeneca Lynparza (olaparib) capsules, prescribing information. 10-4-2015 2015
12. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, K.M. Bell-McGuinn, and et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
13. K.H. Barakat, M.M. Gajewski, and J.A. Tuszynski DNA polymerase beta (pol beta) inhibitors: a comprehensive overview Drug Discov Today 17 2012 913 920
14. K.H. Barakat, L.P. Jordheim, R. Perez-Pineiro, D. Wishart, C. Dumontet, and J.A. Tuszynski Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction PLoS One 7 2012 e51329
15. M.A. Batey, Y. Zhao, S. Kyle, C. Richardson, A. Slade, N.M. Martin, and et al. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer Mol Cancer Ther 12 2013 959 967
16. A.C. Begg, F.A. Stewart, and C. Vens Strategies to improve radiotherapy with targeted drugs Nat Rev Cancer 11 2011 239 253
17. N.R. Bhagwat, V.Y. Roginskaya, M.B. Acquafondata, R. Dhir, R.D. Wood, and L.J. Niedernhofer Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue Cancer Res 69 2009 6831 6838
18. L. Biddlestone-Thorpe, M. Sajjad, E. Rosenberg, J.M. Beckta, N.C. Valerie, M. Tokarz, and et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation Clin Cancer Res 19 2013 3189 3200
19. K. Bixel, and J.L. Hays Olaparib in the management of ovarian cancer Pharmgenomics Pers Med 8 2015 127 135
20. H.J. Boeckman, K.S. Trego, and J.J. Turchi Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining Mol Cancer Res 3 2005 277 285
21. B. Budke, J.H. Kalin, M. Pawlowski, A.S. Zelivianskaia, M. Wu, A.P. Kozikowski, and et al. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity J Med Chem 56 2013 254 263
22. B. Budke, H.L. Logan, J.H. Kalin, A.S. Zelivianskaia, M.W. Cameron, L.L. Miller, and et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells Nucleic Acids Res 40 2012 7347 7357
23. J.J. Caldwell, E.J. Welsh, C. Matijssen, V.E. Anderson, L. Antoni, K. Boxall, and et al. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2 J Med Chem 54 2011 580 590
24. E. Calvo, V.J. Chen, M. Marshall, U. Ohnmacht, S.M. Hynes, E. Kumm, and et al. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer Invest New Drugs 32 2014 955 968
25. R.J. Cardnell, Y. Feng, L. Diao, Y.H. Fan, F. Masrorpour, J. Wang, and et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer Clin Cancer Res 19 2013 6322 6328
26. L. Carlessi, G. Buscemi, E. Fontanella, and D. Delia A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNA damage Biochim Biophys Acta 1803 2010 1213 1223
27. L. Carlessi, G. Buscemi, G. Larson, Z. Hong, J.Z. Wu, and D. Delia Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2 Mol Cancer Ther 6 2007 935 944
28. T.M. Chapman, K.J. Gillen, C. Wallace, M.T. Lee, P. Bakrania, P. Khurana, and et al. Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF Bioorg Med Chem Lett 25 2015 4097 4103
29. J.R. Chapman, M.R. Taylor, and S.J. Boulton Playing the end game: DNA double-strand break repair pathway choice Mol Cell 47 2012 497 510
30. S. Chen, and G. Parmigiani Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 2007 1329 1333
31. X. Chen, S. Zhong, X. Zhu, B. Dziegielewska, T. Ellenberger, G.M. Wilson, and et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair Cancer Res 68 2008 3169 3177
32. A. Chiarugi Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited Trends Pharmacol Sci 23 2002 122 129
33. V.T. Chu, T. Weber, B. Wefers, W. Wurst, S. Sander, K. Rajewsky, and et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells Nat Biotechnol 33 2015 543 548
34. K.M. Clapham, J. Bardos, M.R. Finlay, B.T. Golding, E.J. Griffen, R.J. Griffin, and et al. DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain Bioorg Med Chem Lett 21 2011 966 970
35. S.J. Collis, T.L. DeWeese, P.A. Jeggo, and A.R. Parker The life and death of DNA-PK Oncogene 24 2005 949 961
36. A.I. Daud, M.T. Ashworth, J. Strosberg, J.W. Goldman, D. Mendelson, G. Springett, and et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors J Clin Oncol 33 2015 1060 1066
37. D. Davidson, L. Amrein, L. Panasci, and R. Aloyz Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond Front Pharmacol 4 2013 5
38. C.G. Del, C. Sessa, M.R. von, L. Vigano, T. Digena, A. Locatelli, and et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours Br J Cancer 111 2014 651 659
39. N.C. Del, Y. Xiao, L. Rangell, M. Reichelt, and T. O'Brien Depletion of the central metabolite NAD leads to oncosis-mediated cell death J Biol Chem 289 2014 35182 35192
40. T. Doi, T. Yoshino, K. Shitara, N. Matsubara, N. Fuse, Y. Naito, and et al. Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors Anticancer Drugs 26 2015 1043 1053
41. D. Dorjsuren, D. Kim, V.N. Vyjayanti, D.J. Maloney, A. Jadhav, D.M. Wilson III, and et al. Diverse small molecule inhibitors of human apurinic/apyrimidinic endonuclease APE1 identified from a screen of a large public collection PLoS One 7 2012 e47974
42. H.Q. Duong, Y.B. Hong, J.S. Kim, H.S. Lee, Y.W. Yi, Y.J. Kim, and et al. Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine J Cell Mol Med 17 2013 1261 1270
43. A. Dupre, L. Boyer-Chatenet, R.M. Sattler, A.P. Modi, J.H. Lee, M.L. Nicolette, and et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex Nat Chem Biol 4 2008 119 125
44. C.G. Engelke, L.A. Parsels, Y. Qian, Q. Zhang, D. Karnak, J.R. Robertson, and et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776 Clin Cancer Res 19 2013 4412 4421
45. J. Fan, and N.P. Pavletich Structure and conformational change of a replication protein A heterotrimer bound to ssDNA Genes Dev 26 2012 2337 2347
46. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, and et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
47. E. Fokas, R. Prevo, E.M. Hammond, T.B. Brunner, W.G. McKenna, and R.J. Muschel Targeting ATR in DNA damage response and cancer therapeutics Cancer Treat Rev 40 2014 109 117
48. P.C. Fong, T.A. Yap, D.S. Boss, C.P. Carden, M. Mergui-Roelvink, C. Gourley, and et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2010 2512 2519
49. K.M. Foote, K. Blades, A. Cronin, S. Fillery, S.S. Guichard, L. Hassall, and et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity J Med Chem 56 2013 2125 2138
50. A.O. Frank, B. Vangamudi, M.D. Feldkamp, E.M. Souza-Fagundes, J.W. Luzwick, D. Cortez, and et al. Discovery of a potent stapled helix peptide that binds to the 70N domain of replication protein A J Med Chem 57 2014 2455 2461
51. O.S. Frankfurt, D. Seckinger, and E.V. Sugarbaker Inhibition of DNA repair in cells treated with a combination of alkylating agents Anticancer Res 13 1993 947 952
52. G.K. Freschauf, F. Karimi-Busheri, A. Ulaczyk-Lesanko, T.R. Mereniuk, A. Ahrens, J.M. Koshy, and et al. Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase Cancer Res 69 2009 7739 7746
53. M.D. Garrett, and I. Collins Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 32 2011 308 316
54. K.A. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, K. Tonkin, and et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol 12 2011 852 861
55. J.G. Glanzer, K.A. Carnes, P. Soto, S. Liu, L.J. Parkhurst, and G.G. Oakley A small molecule directly inhibits the p53 transactivation domain from binding to replication protein A Nucleic Acids Res 41 2013 2047 2059
56. J.G. Glanzer, S. Liu, and G.G. Oakley Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods Bioorg Med Chem 19 2011 2589 2595
57. J.G. Glanzer, S. Liu, L. Wang, A. Mosel, A. Peng, and G.G. Oakley RPA inhibition increases replication stress and suppresses tumor growth Cancer Res 74 2014 5165 5172
58. A.G. Goglia, R. Delsite, A.N. Luz, D. Shahbazian, A.F. Salem, R.K. Sundaram, and et al. Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors Mol Cancer Ther 14 2015 326 342
59. S.E. Golding, E. Rosenberg, N. Valerie, I. Hussaini, M. Frigerio, X.F. Cockcroft, and et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion Mol Cancer Ther 8 2009 2894 2902
60. L.J. Goldstein, J. Gurtler, S.A. Del Prete, S. Tjulandin, V.F. Semiglazov, E. Bayever, and et al. Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens Clin Breast Cancer 14 2014 396 404
61. J.F. Goodwin, and K.E. Knudsen Beyond DNA repair: DNA-PK function in cancer Cancer Discov 4 2014 1126 1139
62. S. Grabauskiene, E.J. Bergeron, G. Chen, A.C. Chang, J. Lin, D.G. Thomas, and et al. CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells Lung Cancer 82 2013 477 484
63. M. Graeser, A. McCarthy, C.J. Lord, K. Savage, M. Hills, J. Salter, and et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer Clin Cancer Res 16 2010 6159 6168
64. J.A. Hannay, J. Liu, Q.S. Zhu, S.V. Bolshakov, L. Li, P.W. Pisters, and et al. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation Mol Cancer Ther 6 2007 1650 1660
65. S.J. Haring, A.C. Mason, S.K. Binz, and M.S. Wold Cellular functions of human RPA1. Multiple roles of domains in replication, repair, and checkpoints J Biol Chem 283 2008 19095 19111
66. I. Hickson, Y. Zhao, C.J. Richardson, S.J. Green, N.M. Martin, A.I. Orr, and et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM Cancer Res 64 2004 9152 9159
67. S.K. Ihmaid, J.M. Al-Rawi, C.J. Bradley, M.J. Angove, and M.N. Robertson Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines Eur J Med Chem 57 2012 85 101
68. T. Ishida, Y. Takizawa, T. Kainuma, J. Inoue, T. Mikawa, T. Shibata, and et al. DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange Nucleic Acids Res 37 2009 3367 3376
69. A.S. Jaiswal, S. Banerjee, R. Aneja, F.H. Sarkar, D.A. Ostrov, and S. Narayan DNA polymerase beta as a novel target for chemotherapeutic intervention of colorectal cancer PLoS One 6 2011 e16691
70. A.S. Jaiswal, S. Banerjee, H. Panda, C.D. Bulkin, T. Izumi, F.H. Sarkar, and et al. A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells Mol Cancer Res 7 2009 1973 1983
71. A.S. Jaiswal, H. Panda, B.K. Law, J. Sharma, J. Jani, R. Hromas, and et al. NSC666715 and its analogs inhibit strand-displacement activity of DNA polymerase beta and potentiate temozolomide-induced DNA damage, senescence and apoptosis in colorectal cancer cells PLoS One 10 2015 e0123808
72. M. Javle, and N.J. Curtin The role of PARP in DNA repair and its therapeutic exploitation Br J Cancer 105 2011 1114 1122
73. P. Jeggo, and M.F. Lavin Cellular radiosensitivity: how much better do we understand it? Int J Radiat Biol 85 2009 1061 1081
74. C. Jekimovs, E. Bolderson, A. Suraweera, M. Adams, K.J. O'Byrne, and D.J. Richard Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising Front Oncol 4 2014 86
75. L.P. Jordheim, K.H. Barakat, L. Heinrich-Balard, E.L. Matera, E. Cros-Perrial, K. Bouledrak, and et al. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells Mol Pharmacol. 84 2013 12 24
76. F. Karimi-Busheri, A. Rasouli-Nia, J. lalunis-Turner, and M. Weinfeld Human polynucleotide kinase participates in repair of DNA double-strand breaks by nonhomologous end joining but not homologous recombination Cancer Res 67 2007 6619 6625
77. E.J. Katz, P.A. Andrews, and S.B. Howell The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells Cancer Commun 2 1990 159 164
78. B. Kaufman, R. Shapira-Frommer, R.K. Schmutzler, M.W. Audeh, M. Friedlander, J. Balmana, and et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation J Clin Oncol 33 2015 244 250
79. G. Kaur, R.P. Cholia, A.K. Mantha, and R. Kumar DNA repair and redox activities and inhibitors of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1): a comparative analysis and their scope and limitations toward anticancer drug development J Med Chem 57 2014 10241 10256
80. M.R. Kelley, M.M. Georgiadis, and M.L. Fishel APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1 Curr Mol Pharmacol 5 2012 36 53
81. C. King, H.B. Diaz, S. McNeely, D. Barnard, J. Dempsey, W. Blosser, and et al. LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms Mol Cancer Ther 14 2015 2004 2013
82. S. Kitada, M. Leone, S. Sareth, D. Zhai, J.C. Reed, and M. Pellecchia Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins J Med Chem 46 2003 4259 4264
83. H.L. Klein The consequences of Rad51 overexpression for normal and tumor cells DNA Repair (Amst) 7 2008 686 693
84. R. Krishnakumar, and W.L. Kraus The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets Mol Cell 39 2010 8 24
85. A. Kruczynski, J.M. Barret, H.B. Van, N. Chansard, J. Astruc, Y. Menon, and et al. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II Clin Cancer Res 10 2004 3156 3168
86. I. Kuriyama, A. Miyazaki, Y. Tsuda, H. Yoshida, and Y. Mizushina Inhibitory effect of novel somatostatin peptide analogues on human cancer cell growth based on the selective inhibition of DNA polymerase beta Bioorg Med Chem 21 2013 403 411
87. M. Labroli, K. Paruch, M.P. Dwyer, C. Alvarez, K. Keertikar, C. Poker, and et al. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach - part Bioorg Med Chem Lett 21 2011 471 474
88. M. Lainchbury, T.P. Matthews, T. McHardy, K.J. Boxall, M.I. Walton, P.D. Eve, and et al. Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors J Med Chem 55 2012 10229 10240
89. J.J. Leahy, B.T. Golding, R.J. Griffin, I.R. Hardcastle, C. Richardson, L. Rigoreau, and et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries Bioorg Med Chem Lett 14 2004 6083 6087
90. Y.L. Li, M.P. Carty, G.G. Oakley, M.M. Seidman, M. Medvedovic, and K. Dixon Expression of ATM in ataxia telangiectasia fibroblasts rescues defects in DNA double-strand break repair in nuclear extracts Environ Mol Mutagen 37 2001 128 140
91. T. Li, S.D. Christensen, P.H. Frankel, K.A. Margolin, S.S. Agarwala, T. Luu, and et al. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial Invest New Drugs 30 2012 741 748
92. Y.H. Li, X. Wang, Y. Pan, D.H. Lee, D. Chowdhury, and A.C. Kimmelman Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response PLoS One 7 2012 e39588
93. M. Li, and X. Yu Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation Cancer Cell 23 2013 693 704
94. Q. Liu, H. Jiang, Z. Liu, Y. Wang, M. Zhao, C. Hao, and et al. Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51 PLoS One 6 2011 e23427
95. J.F. Liu, P.A. Konstantinopoulos, and U.A. Matulonis PARP inhibitors in ovarian cancer: current status and future promise Gynecol Oncol 133 2014 362 369
96. J.F. Liu, S.M. Tolaney, M. Birrer, G.F. Fleming, M.K. Buss, S.E. Dahlberg, and et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer Eur J Cancer 49 2013 2972 2978
97. C.J. Lord, A.N. Tutt, and A. Ashworth Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors Annu Rev Med 66 2015 455 470
98. S. Madhusudan, F. Smart, P. Shrimpton, J.L. Parsons, L. Gardiner, S. Houlbrook, and et al. Isolation of a small molecule inhibitor of DNA base excision repair Nucleic Acids Res 33 2005 4711 4724
99. O. Maillard, U. Camenisch, F.C. Clement, K.B. Blagoev, and H. Naegeli DNA repair triggered by sensors of helical dynamics Trends Biochem Sci 32 2007 494 499
100. T. Maruyama, S.K. Dougan, M.C. Truttmann, A.M. Bilate, J.R. Ingram, and H.L. Ploegh Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining Nat Biotechnol 33 2015 538 542
101. J.M. Mason, K. Dusad, W.D. Wright, J. Grubb, B. Budke, W.D. Heyer, and et al. RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells Nucleic Acids Res 43 2015 3180 3196
102. J.M. Mason, H.L. Logan, B. Budke, M. Wu, M. Pawlowski, R.R. Weichselbaum, and et al. The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors Cancer Res 74 2014 3546 3555
103. J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop, R. Perez-Lopez, and et al. DNA-repair defects and olaparib in metastatic prostate cancer N Engl J Med 373 2015 1697 1708
104. L.A. Mathews, S.M. Cabarcas, E.M. Hurt, X. Zhang, E.M. Jaffee, and W.L. Farrar Increased expression of DNA repair genes in invasive human pancreatic cancer cells Pancreas 40 2011 730 739
105. S. McNeely, R. Beckmann, and A.K. Bence Lin CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy Pharmacol Ther 142 2014 1 10
106. E.M. McNeil, K.R. Astell, A.M. Ritchie, S. Shave, D.R. Houston, P. Bakrania, and et al. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance DNA Repair (Amst) 31 2015 19 28
107. A.K. Mishra, S.S. Dormi, A.M. Turchi, D.S. Woods, and J.J. Turchi Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer Biochem Pharmacol 93 2015 25 33
108. A. Mitra, C. Jameson, Y. Barbachano, L. Sanchez, Z. Kote-Jarai, S. Peock, and et al. Overexpression of RAD51 occurs in aggressive prostatic cancer Histopathology 55 2009 696 704
109. Y. Mizushina, H. Suzuki-Fukudome, T. Takeuchi, K. Takemoto, I. Kuriyama, H. Yoshida, and et al. Formosusin A, a novel specific inhibitor of mammalian DNA polymerase beta from the fungus Paecilomyces formosus Bioorg Med Chem 22 2014 1070 1076
110. M.Z. Mohammed, V.N. Vyjayanti, C.A. Laughton, L.V. Dekker, P.M. Fischer, D.M. Wilson III, and et al. Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines Br J Cancer 104 2011 653 663
111. J.M. Munck, M.A. Batey, Y. Zhao, H. Jenkins, C.J. Richardson, C. Cano, and et al. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K Mol Cancer Ther 11 2012 1789 1798
112. J. Murai, S.Y. Huang, B.B. Das, A. Renaud, Y. Zhang, J.H. Doroshow, and et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res 72 2012 5588 5599
113. J. Murai, S.Y. Huang, A. Renaud, Y. Zhang, J. Ji, S. Takeda, and et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Mol Cancer Ther 13 2014 433 443
114. Z. Na, B. Peng, S. Ng, S. Pan, J.S. Lee, H.M. Shen, and et al. A small-molecule protein-protein interaction inhibitor of PARP1 that targets its BRCT domain Angew Chem Int Ed Engl 54 2015 2515 2519
115. T.M. Neher, D. Bodenmiller, R.W. Fitch, S.I. Jalal, and J.J. Turchi Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin Mol Cancer Ther 10 2011 1796 1806
116. T.M. Neher, S.C. Shuck, J. Liu, J.T. Zhang, and J.J. Turchi Identification of novel small molecule inhibitors of the XPA protein using in silico based screening ACS Chem Biol 5 2010 953 965
117. L.J. Niedernhofer, N. Bhagwat, and R.D. Wood ERCC1 and non-small-cell lung cancer N Engl J Med 356 2007 2538 2540
118. B.P. Nutley, N.F. Smith, A. Hayes, L.R. Kelland, L. Brunton, B.T. Golding, and et al. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026 Br J Cancer 93 2005 1011 1018
119. A.M. Oza, D. Cibula, A.O. Benzaquen, C. Poole, R.H. Mathijssen, G.S. Sonke, and et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial Lancet Oncol 16 2015 87 97
120. J. Pal, R. Bertheau, L. Buon, A. Qazi, R.B. Batchu, S. Bandyopadhyay, and et al. Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome Oncogene 30 2011 3585 3598
121. G. Papeo, H. Posteri, D. Borghi, A.A. Busel, F. Caprera, E. Casale, and et al. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoind ole-4-carboxamide (NMS-P118): a potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy J Med Chem 58 2015 6875 6898
122. D. Passeri, E. Camaioni, P. Liscio, P. Sabbatini, M. Ferri, A. Carotti, and et al. Concepts and molecular aspects in the polypharmacology of PARP-1 inhibitors ChemMedChem 2015 10.1002/cmdc.201500391 [Epub ahead of print]
123. E. Pastwa, R.D. Neumann, K. Mezhevaya, and T.A. Winters Repair of radiation-induced DNA double-strand breaks is dependent upon radiation quality and the structural complexity of double-strand breaks Radiat Res 159 2003 251 261
124. A.G. Patel, J.N. Sarkaria, and S.H. Kaufmann Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells Proc Natl Acad Sci U S A 108 2011 3406 3411
125. K.S. Pawelczak, and J.J. Turchi Purification and characterization of exonuclease-free Artemis: implications for DNA-PK-dependent processing of DNA termini in NHEJ-catalyzed DSB repair DNA Repair (Amst) 9 2010 670 677
126. P. Peddi, C.W. Loftin, J.S. Dickey, J.M. Hair, K.J. Burns, K. Aziz, and et al. DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells Free Radic Biol Med 48 2010 1435 1443
127. K.P. Pennington, T. Walsh, M.I. Harrell, M.K. Lee, C.C. Pennil, M.H. Rendi, and et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas Clin Cancer Res 20 2014 764 775
128. L.F. Povirk Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks DNA Repair (Amst) 5 2006 1199 1212
129. R. Prevo, E. Fokas, P.M. Reaper, P.A. Charlton, J.R. Pollard, W.G. McKenna, and et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy Cancer Biol Ther 13 2012 1072 1081
130. C. Qian, M. Li, J. Sui, T. Ren, Z. Li, L. Zhang, and et al. Identification of a novel potential antitumor activity of gossypol as an APE1/Ref-1 inhibitor Drug Des Devel Ther 8 2014 485 496
131. G.B. Qiao, Y.L. Wu, X.N. Yang, W.Z. Zhong, D. Xie, X.Y. Guan, and et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients Br J Cancer 93 2005 137 143
132. E. Raderschall, K. Stout, S. Freier, V. Suckow, S. Schweiger, and T. Haaf Elevated levels of Rad51 recombination protein in tumor cells Cancer Res 62 2002 219 225
133. G. Rai, V.N. Vyjayanti, D. Dorjsuren, A. Simeonov, A. Jadhav, D.M. Wilson III, and et al. Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors J Med Chem 55 2012 3101 3112
134. T. Ren, J. Shan, M. Li, Y. Qing, C. Qian, G. Wang, and et al. Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer Drug Des Devel Ther 9 2015 2887 2910
135. S. Rooney, F.W. Alt, D. Lombard, S. Whitlow, M. Eckersdorff, J. Fleming, and et al. Defective DNA repair and increased genomic instability in artemis-deficient murine cells J Exp Med 197 2003 553 565
136. M. Rouleau, A. Patel, M.J. Hendzel, S.H. Kaufmann, and G.G. Poirier PARP inhibition: PARP1 and beyond Nat Rev Cancer 10 2010 293 301
137. J. San Filippo, P. Sung, and H. Klein Mechanism of eukaryotic homologous recombination Annu Rev Biochem 77 2008 229 257
138. A. Sancar, and J.T. Reardon Nucleotide excision repair in E-coli and man Dna Repair Replication 69 2004 43 71
139. S.K. Sandhu, W.R. Schelman, G. Wilding, V. Moreno, R.D. Baird, S. Miranda, and et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Lancet Oncol 14 2013 882 892
140. C.R. Sears, and J.J. Turchi Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways J Biol Chem 287 2012 24263 24272
141. T. Seto, T. Esaki, F. Hirai, S. Arita, K. Nosaki, A. Makiyama, and et al. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours Cancer Chemother Pharmacol 72 2013 619 627
142. M.A. Shammas, R.J. Shmookler Reis, H. Koley, R.B. Batchu, C. Li, and N.C. Munshi Dysfunctional homologous recombination mediates genomic instability and progression in myeloma Blood 113 2009 2290 2297
143. A. Shibata, D. Moiani, A.S. Arvai, J. Perry, S.M. Harding, M.M. Genois, and et al. DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities Mol Cell 53 2014 7 18
144. S.C. Shuck, and J.J. Turchi Targeted inhibition of replication protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function Cancer Res 70 2010 3189 3198
145. B.L. Sibanda, D.Y. Chirgadze, and T.L. Blundell Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats Nature 463 2010 118 121
146. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
147. H. Song, E. Dicks, S.J. Ramus, J.P. Tyrer, M.P. Intermaggio, J. Hayward, and et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population J Clin Oncol 33 2015 2901 2907
148. A. Sonnenblick, A.E. de, H.A. Azim Jr., and M. Piccart An update on PARP inhibitors - moving to the adjuvant setting Nat Rev Clin Oncol 12 2015 27 41
149. A. Srinivasan, L. Wang, C.J. Cline, Z. Xie, R.W. Sobol, X.Q. Xie, and B. Gold Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors Biochemistry 51 2012 6246 6259
150. M. Srivastava, M. Nambiar, S. Sharma, S.S. Karki, G. Goldsmith, M. Hegde, and et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression Cell 151 2012 1474 1487
151. G.C. Stachelek, E. Peterson-Roth, Y. Liu, R.J. Fernandez III, L.R. Pike, J.M. Qian, and et al. YU238259 is a novel inhibitor of homology-dependent DNA repair that exhibits synthetic lethality and radiosensitization in repair-deficient tumors Mol Cancer Res 13 2015 1389 1397
152. D. Svilar, E.M. Goellner, K.H. Almeida, and R.W. Sobol Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage Antioxid Redox Signal 12 2010 2491 2507
153. M. Takaku, T. Kainuma, T. Ishida-Takaku, S. Ishigami, H. Suzuki, S. Tashiro, and et al. Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51 Genes Cells 16 2011 427 436
154. T. Takenaka, I. Yoshino, H. Kouso, T. Ohba, T. Yohena, A. Osoegawa, and et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer Int J Cancer 121 2007 895 900
155. P. Tennstedt, R. Fresow, R. Simon, A. Marx, L. Terracciano, C. Petersen, and et al. RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma Int J Cancer 132 2013 2118 2126
156. F.P. Vendetti, A. Lau, S. Schamus, T.P. Conrads, M.J. O'Connor, and C.J. Bakkenist The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo Oncotarget 6 2015 44289 44305
157. A.R. Venkitaraman Cancer suppression by the chromosome custodians, BRCA1 and BRCA2 Science 343 2014 1470 1475
158. L. Wahba, S.K. Gore, and D. Koshland The homologous recombination machinery modulates the formation of RNA-DNA hybrids and associated chromosome instability Elife 2 2013 e00505
159. S.S. Wallace Base excision repair: a critical player in many games DNA Repair (Amst) 19 2014 14 26
160. A.T. Wang, T. Kim, J.E. Wagner, B.A. Conti, F.P. Lach, A.L. Huang, and et al. A dominant mutation in human RAD51 reveals its function in DNA interstrand crosslink repair independent of homologous recombination Mol Cell 59 2015 478 490
161. H. Wang, H. Wang, S.N. Powell, G. Iliakis, and Y. Wang ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining Cancer Res 64 2004 7139 7143
162. A.G. Waterson, J.P. Kennedy, J.D. Patrone, N.F. Pelz, M.D. Feldkamp, A.O. Frank, and et al. Diphenylpyrazoles as replication protein a inhibitors ACS Med Chem Lett 6 2015 140 145
163. A.M. Weber, and A.J. Ryan ATM and ATR as therapeutic targets in cancer Pharmacol Ther 149 2015 124 138
164. G.J. Weiss, R.C. Donehower, T. Iyengar, R.K. Ramanathan, K. Lewandowski, E. Westin, and et al. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer Invest New Drugs 31 2013 136 144
165. A.P. Wiegmans, F. Al-Ejeh, N. Chee, P.Y. Yap, J.J. Gorski, S.L. Da, and et al. Rad51 supports triple negative breast cancer metastasis Oncotarget 5 2014 3261 3272
166. E. Willmore, C.S. de, N.J. Sunter, M.J. Tilby, G.H. Jackson, C.A. Austin, and et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia Blood 103 2004 4659 4665
167. D. Woods, and J.J. Turchi Chemotherapy induced DNA damage response: convergence of drugs and pathways Cancer Biol Ther 14 2013 379 389
168. J. Yelamos, J. Farres, L. Llacuna, C. Ampurdanes, and J. Martin-Caballero PARP-1 and PARP-2: new players in tumour development Am J Cancer Res 1 2011 328 346
169. J. Yelamos, V. Schreiber, and F. Dantzer Toward specific functions of poly(ADP-ribose) polymerase-2 Trends Mol Med 14 2008 169 178
170. T. Zaremba, and N.J. Curtin PARP inhibitor development for systemic cancer targeting Anticancer Agents Med Chem 7 2007 515 523
171. H. Zhao, K.R. Luoto, A.X. Meng, and R.G. Bristow The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination Radiother Oncol 101 2011 59 65
172. Y. Zhao, H.D. Thomas, M.A. Batey, I.G. Cowell, C.J. Richardson, R.J. Griffin, and et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441 Cancer Res 66 2006 5354 5362
173. J. Zhu, H. Chen, X.E. Guo, X.L. Qiu, C.M. Hu, A.R. Chamberlin, and et al. Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors Eur J Med Chem 96 2015 196 208
174. J. Zhu, L. Zhou, G. Wu, H. Konig, X. Lin, G. Li, and et al. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia EMBO Mol Med 5 2013 353 365